Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007095 (carcinoid)
 6,990 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

One hundred and one cases of lung cancer were immunohistochemically studied for stainability with Leu-7 (anti-myelin fiber associated glycoprotein) and OKT-9 (anti-transferrin receptor) monoclonal antibodies. All small cell carcinomas and carcinoid tumors were positively stained by Leu-7, and 22 of 41 differentiated adenocarcinomas were also positively stained, especially well-differentiated Clara cell-type adenocarcinoma, (11/14 cases). However, only one of 26 squamous cell carcinomas, one of six large cell carcinomas, one of six adenosquamous carcinomas and none of 16 poorly differentiated adenocarcinomas were stained by Leu-7. On the other hand, all squamous cell carcinomas (26/26 cases), 10 of the 16 poorly differentiated adenocarcinomas, four of the six large cell carcinomas showed positive membranous staining with OKT-9. However, only one of 41 differentiated adenocarcinomas and no small cell carcinomas nor carcinoid tumors were stained by OKT-9. The stainability of lung cancer by these antibodies is discussed.
 ...
PMID:Stainability of lung cancer cells with Leu-7 and OKT-9 monoclonal antibodies. 241 90

NKH-1 is a monoclonal antibody that reacts with human natural killer (NK) cells and neural tissue. Because other monoclonal antibodies reacting with NK cells have been found on small cell lung carcinoma (SCLC), frozen tissue sections of 22 lung tumors including nine SCLC, two bronchial carcinoids, and 11 non-SCLC were tested for the presence of NKH-1 antigen by a sensitive alkaline phosphatase/anti-alkaline phosphatase technique. The labeling reactions of NKH-1 in frozen tissue sections were compared with reactions of a panel of 21 other monoclonal antibodies against NK cells, leukocyte antigens, cytokeratins, or nonlineage specific antigens. The antibody NKH-1 reacted strongly and diffusely with all of the SCLC and bronchial carcinoids but with none of the non-SCLC. NKH-1 also strongly labeled peripheral nerves in tissues adjacent to tumor. Two antibodies to cytokeratins reacted with all of the tumors and outlined tumor cells well, distinguishing them from surrounding stromal cells and leukocytes. OKT9, an antibody against transferrin receptor labeled all SCLC and eight of 11 non-SCLC but did not react with bronchial carcinoid. The antibodies Leu-M1, OKT10, Leu-7, and My4 reacted with 67%, 33%, 22%, and 11%, respectively, of the SCLC tested. The remaining 14 antibodies, including several with leukocyte specificity, labeled neither SCLC nor bronchial carcinoid. Thus, SCLC has a distinct immunophenotype (NKH-1 positive, keratin positive, and transferrin receptor positive), which may be helpful distinguishing this tumor from other tumors of lung including non-SCLC. SCLC infrequently expresses other leukocyte-associated antigens.
 ...
PMID:Immunophenotype of small cell lung carcinoma. Expression of NKH-1 and transferrin receptor and absence of most myeloid antigens. 284 86